CSF_RA_Highlights_EULAR2022

EULAR 2022
Congress Preview
Rheumatoid Arthritis
Chairman’s Introduction
Dear CSF Member,
Welcome to this year’s selection of EULAR abstracts on cytokine signalling agents available for use in RA. In this brochure
you’ll find 35 recommended abstracts and 12 of my special ‘Chairman’s Picks’… making a total of 47 abstracts for you to
look out for!
Amongst the Day 1 abstracts, you’ll find oral presentations by Prof. Maxime Dougados, who discusses the effect of
tofacitinib on pain (OP0052), and Dr Lorenzo Beretta who discusses RNAseq processing to predict response to tofacitinib
(OP0089). We’ve also selected a number of posters for you to take a look at including efficacy data for baricitinib (POS0666),
filgotinib (POS0678 and POS0679), upadacitinib (POS0693), and tofacitinib (POS0657)
Adverse events have been a hot topic following ORAL Surveillance, and on Day 2 there are a couple of oral presentations
on this you might not want to miss. Dr Yvette Meissner will be taking us through CV data from the German RABBIT register
(OP0135), while Dr Juan Molina Collada talks about cancer risk after treatment with biologic and targeted synthetic DMARDs
(OP0138). There are further abstracts on adverse events on Day 3, including studies of tofacitinib (OP0264 and POS0239),
filgotinib (POS0235) and other JAK inhibitors (OP0266 and OP0268).
This year, we’re producing separate highlights brochures for PsA and axSpA, so make sure to go to the Cytokine Signalling
Forum and download our other highlights brochures. If you’re looking for the latest on lupus, head over to
https://www.lupus-forum.com/ where you’ll find their EULAR selections.
As always, thank you for your continued support, and we hope you enjoy what will be – for many – the first in-person
congress in 2 years!
Kind regards
Professor Iain McInnes
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Key Presentations
Wednesday, 01 June 2022
All day POSTER VIEW 2
POS0519
POS0513
POS0518
Relationship between disease activity and major
adverse events in patients with rheumatoid arthritis
on tofacitinib or TNF inhibitors: a post hoc analysis of
ORAL Surveillance
George Karpouzas
Safety of filgotinib in patients with rheumatoid arthritis:
Analysis of lymphocytes in the long-term extension
FINCH 4 study
Jacques-Eric Gottenberg
Effect of filgotinib (FIL) on body weight (BW) and body
mass index (BMI) and effect of baseline BMI on the
efficacy and safety of FIL in rheumatoid arthritis (RA)
Alejandro Balsa
All day POSTER VIEW 3
POS0639
POS0657
POS0663
POS0664
POS0665
POS0666
Pharmacokinetic boosting to enable a once-daily
reduced dose of tofacitinib in patients with rheumatoid
arthritis and psoriatic arthritis
Celeste van der Togt
Survival of baricitinib vs anti-TNF as the first biological
drug in patients with rheumatoid arthritis, in clinical
practice: results of a local registry
Jose Rosas
The use of exposure-adjusted event rates versus
exposure-adjusted incidence rates in adverse event
reporting: insights from filgotinib integrated safety data
in rheumatoid arthritis
Patrick Durez
Radiographic change in patients with rheumatoid
arthritis and estimated baseline yearly progression ≥5 or
<5: post hoc analysis of two phase 3 trials of filgotinib
Yoshiya Tanaka
Development of a biochemical tofacitinib adherence
assay in rheumatoid arthritis: The ORAL adhere study
James Bluett
A multinational, prospective, observational study in
patients with rheumatoid arthritis receiving baricitinib,
targeted synthetic or biologic disease-modifying
therapies: 12 month time to discontinuation,
effectiveness and patient reported outcome data from
the European cohort
Rieke Alten
POS0668
POS0671
POS0673
POS0676
POS0678
POS0679
POS0682
POS0691
The efficacy of tofacitinib on clinical dynamic and
concentration of cytokines in patients with
rheumatoid arthritis
N Lapkina
Impact of race on the efficacy and safety of tofacitinib
in patients with rheumatoid arthritis: a post hoc
analysis of Phase 2, 3 and 3b/4 clinical trials
Grace C. Wright
Endothelial inflammation in rheumatoid arthritis
patients treated with tofacitinib
Maria DeLaVega
Efficacy and safety of filgotinib in patients aged
≥75 years: a post hoc subgroup analysis of the
FINCH 4 long-term extension (LTE) study
Daniel Aletaha
Clinical outcomes of methotrexate (MTX)-naïve
rheumatoid arthritis (RA) patients (pts) on filgotinib
(FIL) long-term extension (LTE) trial initially on FIL or
MTX during the Phase 3 parent study (PS)
Daniel Aletaha
Clinical outcomes up to Week (W) 48 in the ongoing
filgotinib (FIL) long-term extension (LTE) trial of
rheumatoid arthritis (RA) patients (pts) with inadequate
response (IR) to methotrexate (MTX) initially treated
with FIL or adalimumab (ADA) during the Phase 3
parent study (PS)
Bernard Combe
Long-term efficacy of baricitinib in patients with
rheumatoid arthritis with inadequate response to
bDMARDs: results from RA-BEYOND following
6.9-years of treatment
Roberto Caporali
Emulating a target trial of adalimumab versus
tofacitinib in patients with rheumatoid arthritis:
A comparative effectiveness analysis using the OPAL
real-world dataset
Claire Deakin

Chairman’s Picks
All day POSTER VIEW 4
POS0693
POS0704
POS0701
POS0699
POS0694
14:15–
15:30
–
14:15–
15:30
–
16:30–
18:00
OP0052
16:30–
18:00
OP0089
Impact of upadacitinib versus abatacept on individual
disease outcomes in patients with rheumatoid arthritis
and inadequate responses to biologic DMARDs
Ronald van Vollenhoven
Efficacy and safety of filgotinib in patients with
inadequate response to methotrexate, with 4 or <4
poor prognostic factors: A post hoc analysis of the
FINCH 1 study
Bernard Combe
Long-term efficacy of baricitinib in patients with
rheumatoid arthritis who have had inadequate
response to csDMARDs: results from RA-BEYOND up
to 7 years of treatment
Roberto Caporali
Similar efficacy and drug survival rates of baricitinib
monotherapy and baricitinib/ methotrexate
combination therapy in real-life treatment of
rheumatoid arthritis- results from a prospective cohort
of baricitinib-treated patients
Sara Bayat
What treatment gives the best clinical response after
cessation of JAKi therapy in patients with RA?
Data of the TARDIS-RA registry, a nationwide Belgian
Biologic registry
Diederik De Cock
EULAR RECOMMENDATIONS SESSION
Update of the EULAR recommendations on the
management of rheumatoid arthritis
Josef S. Smolen
SOCIAL MEDIA AND DIGITAL SOURCES IN
RHEUMATOLOGY
Keeping up with podcasts as an educational and
academic tool
Michael Putman
MANAGING CHRONIC PAIN IN RMDs
The effect of tofacitinib on residual pain in patients
with rheumatoid arthritis and psoriatic arthritis with
complete control of inflammation
Maxime Dougados
RHEUMATOID ARTHRITIS–PROGNOSIS AND
PREDICTION
RNAseq profiling of rheumatoid arthritis patients to
predict response to tofacitinib
Lorenzo Beretta
Thursday, 02 June 2022
10:30–
12:00
OP0135
OP0138
12:00–
13:30
POS0105
15:45–
17:00
–
RA: CLINICAL ASPECTS AND
COMORBIDITIES – 1
Risk of cardiovascular events under Janus kinase
inhibitors in patients with rheumatoid arthritis:
observational data from the German RABBIT register
Yvette Meissner
Risk of cancer after biologic and targeted synthetic
DMARDs initiation in patients with rheumatic diseases
and a history of prior malignancy: data from the
BIOBADASER registry
Juan Molina Collada
POSTER TOUR AUDITORIUM 6:
RHEUMATOID ARTHRITIS – PROGNOSIS,
PREDICTORS AND OUTCOME
Immunological and tissue derived biomarkers of early
response in moderate-to-severe rheumatoid arthritis
treated with JAK-inhibitors
Simone Perniola
SARCOPENIA IN THE CLINICAL
EXPRESSION OF RHEUMATIC DISEASES
AND ITS TREATMENT
JAK-Stat pathway inhibition in rheumatoid arthritis:
The creatine kinase paradox
Aranzazu Mediero
Friday, 03 June 2022
10:30–
12:00
OP0264
OP0265
OP0266
RA TREATMENT: MODERN STRATEGIES
AND NEW MOLECULES
Impact of baseline cardiovascular risk on the incidence
of major adverse cardiovascular events in the
tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados
Comparison of the effect of different Janus kinase
inhibitors on activation, function and property of
NK cells to control cancer cell lines proliferation:
an ex vivo and in vitro study.
Loïc Meudec
Treatment discontinuation due to adverse events as
an overall measure of tolerance and safety of JAKinhibitors:
An international collaboration of registries of
rheumatoid arthritis patients (the “JAK-pot” study).
Eric Nham

Chairman’s Picks
OP0268
10:30–
12:00
OP0276
10:30–
12:00
OP0213-
HPR
10:30–
12:00
OP0269
11:23–
12:00
–
12:00–
13:30
POS0235
POS0239
Comparison of major cardiovascular and
thromboembolic events in safety reports between
rheumatoid arthritis patients treated with JAKinhibitors
versus anti-TNF: results from VigiBase ®
Adeline Ruyssen-Witrand
RA: CLINICAL ASPECTS AND
COMORBIDITIES–II
Preferences for treatments to prevent rheumatoid
arthritis: Discrete choice survey of rheumatoid arthritis
patients’ first-degree relatives in the United Kingdom
and Germany
Marie Falahee
HPR INTERVENTIONS ON THE SPOTLIGHT
Recommendations for nurses in the management of
RA patients on treatment with jakinibs
Silvia García-Díaz
RA TREATMENT: MODERN STRATEGIES
AND NEW MOLECULES
Biomarkers to predict risk of venous thromboembolism
in patients with rheumatoid arthritis receiving
tofacitinib or tumour necrosis factor inhibitors
Zoltán Szekanecz
HOW TO TREAT CHRONIC PAIN IN RMDs
How to treat chronic pain in RMDs
Lesley Colvin
POSTER TOUR AUDITORIUM 6:
RHEUMATOID ARTHRITIS: JAKI AND BEYOND
Integrated safety analysis update for filgotinib (FIL)
in patients (pts) with moderately to severely active
rheumatoid arthritis (RA) receiving treatment over a
median of 2.2 years (y)
Jacques-Eric Gottenberg
Risk of venous thromboembolic events in patients
with rheumatoid arthritis aged ≥50 years with ≥1
cardiovascular risk factor: results from a Phase 3b/4
randomised study of tofacitinib vs tumour necrosis
factor inhibitors
Christina Charles-Schoeman
POS0241
POS0242
13:30–
14:07
–
13:30–
14:45
–
Jak inhibitors in patients with active rheumatoid
arthritis: exploring early response on central
sensitization and catastrophism symptoms
Fausto Salaffi
The effect of antimalarials on the overall safety and
persistence of treatment with biologic agents or JAK
inhibitors in rheumatoid arthritis
Markus Bredemeier
JAK INHIBITORS: ARE ALL PROMISES
FULFILLED?
JAKi: are all promises fulfilled?
Hendrik Schulze-Koops
DRUG REPURPOSING IN RHEUMATOLOGY:
FROM BENCH TO BEDSIDE
Janus Kinase Inhibitors: Ja(c)k of all trades?
Peter Nash
Saturday, 04 June 2022
09:00–
10:15
–
12:00–
13:30
POS0345
12:00–
13:30
POS0290
NEUROPATHIC PAIN IN RMDs
Neuroinflammation and neuropathic pain mechanisms
in rheumatoid arthritis
Camilla Svensson
POSTER TOUR AUDITORIUM 6:
RHEUMATOID ARTHRITIS: JAKI AND BEYOND
Assessment of the effect of Tofacitinib on bone
marrow adipocytes and bone-forming osteoblasts
under non-inflammatory and inflammatory conditions
Jean-Guillaume Letarouilly
POSTER TOUR AUDITORIUM 6:
RHEUMATOID ARTHRITIS: JAKI AND BEYOND
The effects of treatment response and risk factor to
inhibit the clinical response in patients with difficultto-treat
rheumatoid arthritis treated with IL-6 receptor
inhibitor, abatacept and JAK inhibitor
Shohei Anno
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum